Cargando…

Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study

BACKGROUND: Tumor immune-evasion and associated failure of immunotherapy can potentially be overcome by radiotherapy, which however also has detrimental effects on tumor-infiltrating and circulating lymphocytes (CL). We therefore established a model to simulate the radiation-dose delivered to CL. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Basler, L., Andratschke, N., Ehrbar, S., Guckenberger, M., Tanadini-Lang, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778751/
https://www.ncbi.nlm.nih.gov/pubmed/29357886
http://dx.doi.org/10.1186/s13014-018-0952-y
_version_ 1783294418465325056
author Basler, L.
Andratschke, N.
Ehrbar, S.
Guckenberger, M.
Tanadini-Lang, S.
author_facet Basler, L.
Andratschke, N.
Ehrbar, S.
Guckenberger, M.
Tanadini-Lang, S.
author_sort Basler, L.
collection PubMed
description BACKGROUND: Tumor immune-evasion and associated failure of immunotherapy can potentially be overcome by radiotherapy, which however also has detrimental effects on tumor-infiltrating and circulating lymphocytes (CL). We therefore established a model to simulate the radiation-dose delivered to CL. METHODS: A MATLAB-model was established to quantify the CL-dose during SBRT of liver metastases by considering the factors: hepatic blood-flow, −velocity and transition-time of individual hepatic segments, as well as probability-based recirculation. The effects of intra-hepatic tumor-location and size, fractionation and treatment planning parameters (VMAT, 3DCRT, photon-energy, dose-rate and beam-on-time) were analyzed. A threshold dose ≥0.5Gy was considered inactivating CL and CL0.5 (%) is the proportion of inactivated CL. RESULTS: Mean liver dose was mostly influenced by treatment-modality, whereas CL0.5 was mostly influenced by beam-on-time. 3DCRT and VMAT (10MV-FFF) resulted in lowest CL0.5 values of 16 and 19%. Metastasis location influenced CL0.5, with a mean of 19% for both apical and basal and 31% for the central location. PTV-volume significantly increased CL0.5 from 27 to 67% (10MV-FFF) and from 31 to 98% (6MV-FFF) for PTV-volumes ranging from 14cm(3) to 268cm(3). CONCLUSION: A simulation-model was established, quantifying the strong effects of treatment-technique, tumor-location and tumor-volume on dose to CL with potential implications for immune-optimized treatment-planning in the future. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1186/s13014-018-0952-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5778751
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57787512018-01-31 Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study Basler, L. Andratschke, N. Ehrbar, S. Guckenberger, M. Tanadini-Lang, S. Radiat Oncol Research BACKGROUND: Tumor immune-evasion and associated failure of immunotherapy can potentially be overcome by radiotherapy, which however also has detrimental effects on tumor-infiltrating and circulating lymphocytes (CL). We therefore established a model to simulate the radiation-dose delivered to CL. METHODS: A MATLAB-model was established to quantify the CL-dose during SBRT of liver metastases by considering the factors: hepatic blood-flow, −velocity and transition-time of individual hepatic segments, as well as probability-based recirculation. The effects of intra-hepatic tumor-location and size, fractionation and treatment planning parameters (VMAT, 3DCRT, photon-energy, dose-rate and beam-on-time) were analyzed. A threshold dose ≥0.5Gy was considered inactivating CL and CL0.5 (%) is the proportion of inactivated CL. RESULTS: Mean liver dose was mostly influenced by treatment-modality, whereas CL0.5 was mostly influenced by beam-on-time. 3DCRT and VMAT (10MV-FFF) resulted in lowest CL0.5 values of 16 and 19%. Metastasis location influenced CL0.5, with a mean of 19% for both apical and basal and 31% for the central location. PTV-volume significantly increased CL0.5 from 27 to 67% (10MV-FFF) and from 31 to 98% (6MV-FFF) for PTV-volumes ranging from 14cm(3) to 268cm(3). CONCLUSION: A simulation-model was established, quantifying the strong effects of treatment-technique, tumor-location and tumor-volume on dose to CL with potential implications for immune-optimized treatment-planning in the future. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1186/s13014-018-0952-y) contains supplementary material, which is available to authorized users. BioMed Central 2018-01-22 /pmc/articles/PMC5778751/ /pubmed/29357886 http://dx.doi.org/10.1186/s13014-018-0952-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Basler, L.
Andratschke, N.
Ehrbar, S.
Guckenberger, M.
Tanadini-Lang, S.
Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study
title Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study
title_full Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study
title_fullStr Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study
title_full_unstemmed Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study
title_short Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study
title_sort modelling the immunosuppressive effect of liver sbrt by simulating the dose to circulating lymphocytes: an in-silico planning study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778751/
https://www.ncbi.nlm.nih.gov/pubmed/29357886
http://dx.doi.org/10.1186/s13014-018-0952-y
work_keys_str_mv AT baslerl modellingtheimmunosuppressiveeffectofliversbrtbysimulatingthedosetocirculatinglymphocytesaninsilicoplanningstudy
AT andratschken modellingtheimmunosuppressiveeffectofliversbrtbysimulatingthedosetocirculatinglymphocytesaninsilicoplanningstudy
AT ehrbars modellingtheimmunosuppressiveeffectofliversbrtbysimulatingthedosetocirculatinglymphocytesaninsilicoplanningstudy
AT guckenbergerm modellingtheimmunosuppressiveeffectofliversbrtbysimulatingthedosetocirculatinglymphocytesaninsilicoplanningstudy
AT tanadinilangs modellingtheimmunosuppressiveeffectofliversbrtbysimulatingthedosetocirculatinglymphocytesaninsilicoplanningstudy